Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation Durable volume reduction was demonstrated with an ...
As part of Thyroid Nodule Awareness Week, Dr. Roy will host a LIVE Q&A session on Facebook February 26 to answer questions directly from patients and families. Thyroid nodules are extremely common, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results